Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ563563,5-0,79
KB901,59020,33
PKN98,1498,24-1,86
Msft112,4112,45-0,67
Nokia4,6284,636-4,29
IBM148148,90,27
Daimler AG55,8655,880,20
PFE43,3243,55-0,41
19.9.2018 14:51:56
Indexy online
AD Index online
select
AD Index online
 

  • 12.9.2018 19:23:08
Xencor (Stuttgart)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
38,90 -0,96 -0,37 1 673
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.9.2018
Popis společnosti
Obecné informace
Název společnostiXencor Inc
TickerXNCR
Kmenové akcie:Ordinary Shares
RICXNCR.O
ISINUS98401F1057
Prioritní akcieConv. Pref. Shrs Series A-1
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs
Prioritní akcieOrdinary Shares
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.6.2018
Počet zaměstnanců k 31.12.2017 114
Akcie v oběhu k 1.8.2018 55 826 112
Počet akcionářů k 31.3.2018 209
MěnaUSD
Kontaktní informace
Ulice111 W Lemon Ave
MěstoMONROVIA
PSČ91016-2809
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 263 055 900
Fax16263050350

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
Financial Summary: BRIEF: For the six months ended 30 June 2018, Xencor Inc revenues decreased from $16M to $0K. Net loss increased from $23.2M to $55.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and Development - Balancing val increase of 54% to $43.4M (expense), Stock-based Compensation in R&D increase of 62% to $6M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 19.9.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Founder, DirectorBassil Dahiyat471.1.1997
Senior Vice President, Research and Chief Scientific OfficerJohn Desjarlais53
Senior Vice President, Chief Medical OfficerPaul Foster64
Vice President - FinanceJohn Kuch58